FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022969440> ?p ?o ?g. }

• W3022969440 endingPage "145.e6" @default.
• W3022969440 startingPage "136" @default.
• W3022969440 abstract "Background & AimsFactors that affect outcomes of patients with nonalcoholic steatohepatitis (NASH)-related cirrhosis are unclear. We studied associations of type 2 diabetes, levels of hemoglobin A1c (HbA1c), and use of antidiabetic medications with survival and liver-related events in patients with NASH and compensated cirrhosis.MethodsWe collected data from 299 patients with biopsy-proven NASH with Child–Pugh A cirrhosis from tertiary hospitals in Spain, Australia, Hong Kong, and Cuba, from April 1995 through December 2016. We obtained information on the presence of type 2 diabetes, level of HbA1c, and use of antidiabetic medications. Cox proportional and competing risk models were used to estimate and compare rates of transplant-free survival, hepatic decompensation, and hepatocellular carcinoma (HCC).ResultsA total of 212 patients had type 2 diabetes at baseline and 8 of 87 patients developed diabetes during a median follow-up time of 5.1 years (range, 0.5–10.0 y). A lower proportion of patients with diabetes survived the entire follow-up period (38%) than of patients with no diabetes (81%) (adjusted hazard ratio [aHR], 4.23; 95% CI, 1.93–9.29). Higher proportions of patients with diabetes also had hepatic decompensation (51% vs 26% of patients with no diabetes; aHR, 2.03; 95% CI, 1.005–4.11) and HCC (25% vs 7% of patients with no diabetes; aHR, 5.42; 95% CI, 1.74–16.80). Averaged annual HbA1c levels over time were not associated with outcomes. Metformin use over time was associated with a significant reduction in risk of death or liver transplantation (aHR, 0.41; 95% CI, 0.26–0.45), hepatic decompensation (aHR, 0.80; 95% CI, 0.74–0.97), and HCC (aHR, 0.78; 95% CI, 0.69–0.96). Metformin significantly reduced the risk of hepatic decompensation and HCC only in subjects with HbA1c levels greater than 7.0% (aHR, 0.97; 95% CI, 0.95–0.99 and aHR, 0.67; 95% CI, 0.43–0.94, respectively).ConclusionsIn an international cohort of patients with biopsy-proven NASH and Child–Pugh A cirrhosis, type 2 diabetes increased the risk of death and liver-related outcomes, including HCC. Patients who took metformin had higher rates of survival and lower rates of decompensation and HCC. Factors that affect outcomes of patients with nonalcoholic steatohepatitis (NASH)-related cirrhosis are unclear. We studied associations of type 2 diabetes, levels of hemoglobin A1c (HbA1c), and use of antidiabetic medications with survival and liver-related events in patients with NASH and compensated cirrhosis. We collected data from 299 patients with biopsy-proven NASH with Child–Pugh A cirrhosis from tertiary hospitals in Spain, Australia, Hong Kong, and Cuba, from April 1995 through December 2016. We obtained information on the presence of type 2 diabetes, level of HbA1c, and use of antidiabetic medications. Cox proportional and competing risk models were used to estimate and compare rates of transplant-free survival, hepatic decompensation, and hepatocellular carcinoma (HCC). A total of 212 patients had type 2 diabetes at baseline and 8 of 87 patients developed diabetes during a median follow-up time of 5.1 years (range, 0.5–10.0 y). A lower proportion of patients with diabetes survived the entire follow-up period (38%) than of patients with no diabetes (81%) (adjusted hazard ratio [aHR], 4.23; 95% CI, 1.93–9.29). Higher proportions of patients with diabetes also had hepatic decompensation (51% vs 26% of patients with no diabetes; aHR, 2.03; 95% CI, 1.005–4.11) and HCC (25% vs 7% of patients with no diabetes; aHR, 5.42; 95% CI, 1.74–16.80). Averaged annual HbA1c levels over time were not associated with outcomes. Metformin use over time was associated with a significant reduction in risk of death or liver transplantation (aHR, 0.41; 95% CI, 0.26–0.45), hepatic decompensation (aHR, 0.80; 95% CI, 0.74–0.97), and HCC (aHR, 0.78; 95% CI, 0.69–0.96). Metformin significantly reduced the risk of hepatic decompensation and HCC only in subjects with HbA1c levels greater than 7.0% (aHR, 0.97; 95% CI, 0.95–0.99 and aHR, 0.67; 95% CI, 0.43–0.94, respectively). In an international cohort of patients with biopsy-proven NASH and Child–Pugh A cirrhosis, type 2 diabetes increased the risk of death and liver-related outcomes, including HCC. Patients who took metformin had higher rates of survival and lower rates of decompensation and HCC." @default.
• W3022969440 created "2020-05-13" @default.
• W3022969440 creator A5011865871 @default.
• W3022969440 creator A5025140652 @default.
• W3022969440 creator A5046528197 @default.
• W3022969440 creator A5058541785 @default.
• W3022969440 creator A5071565406 @default.
• W3022969440 creator A5077107478 @default.
• W3022969440 creator A5079574961 @default.
• W3022969440 creator A5083278515 @default.
• W3022969440 creator A5087968813 @default.
• W3022969440 creator A5090087138 @default.
• W3022969440 date "2021-01-01" @default.
• W3022969440 modified "2023-10-18" @default.
• W3022969440 title "Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis–Related, Child–Pugh A Cirrhosis" @default.
• W3022969440 cites W1699944894 @default.
• W3022969440 cites W1776128289 @default.
• W3022969440 cites W1964572117 @default.
• W3022969440 cites W1985559199 @default.
• W3022969440 cites W1987041848 @default.
• W3022969440 cites W1988051941 @default.
• W3022969440 cites W1997303839 @default.
• W3022969440 cites W2001837599 @default.
• W3022969440 cites W2002004237 @default.
• W3022969440 cites W2019093082 @default.
• W3022969440 cites W2026967508 @default.
• W3022969440 cites W2029691295 @default.
• W3022969440 cites W2033976318 @default.
• W3022969440 cites W2057847137 @default.
• W3022969440 cites W2061273963 @default.
• W3022969440 cites W2063437798 @default.
• W3022969440 cites W2067681932 @default.
• W3022969440 cites W2067740038 @default.
• W3022969440 cites W2100358697 @default.
• W3022969440 cites W2113676816 @default.
• W3022969440 cites W2118941971 @default.
• W3022969440 cites W2119553987 @default.
• W3022969440 cites W2143756124 @default.
• W3022969440 cites W2218877772 @default.
• W3022969440 cites W2288971050 @default.
• W3022969440 cites W2508708811 @default.
• W3022969440 cites W2594571857 @default.
• W3022969440 cites W2734724639 @default.
• W3022969440 cites W2738659466 @default.
• W3022969440 cites W2772546925 @default.
• W3022969440 cites W2782332756 @default.
• W3022969440 cites W2800368679 @default.
• W3022969440 cites W2884323913 @default.
• W3022969440 cites W2948364100 @default.
• W3022969440 cites W3143409077 @default.
• W3022969440 cites W571628560 @default.
• W3022969440 doi "https://doi.org/10.1016/j.cgh.2020.04.083" @default.
• W3022969440 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32389886" @default.
• W3022969440 hasPublicationYear "2021" @default.
• W3022969440 type Work @default.
• W3022969440 sameAs 3022969440 @default.
• W3022969440 citedByCount "41" @default.
• W3022969440 countsByYear W30229694402020 @default.
• W3022969440 countsByYear W30229694402021 @default.
• W3022969440 countsByYear W30229694402022 @default.
• W3022969440 countsByYear W30229694402023 @default.
• W3022969440 crossrefType "journal-article" @default.
• W3022969440 hasAuthorship W3022969440A5011865871 @default.
• W3022969440 hasAuthorship W3022969440A5025140652 @default.
• W3022969440 hasAuthorship W3022969440A5046528197 @default.
• W3022969440 hasAuthorship W3022969440A5058541785 @default.
• W3022969440 hasAuthorship W3022969440A5071565406 @default.
• W3022969440 hasAuthorship W3022969440A5077107478 @default.
• W3022969440 hasAuthorship W3022969440A5079574961 @default.
• W3022969440 hasAuthorship W3022969440A5083278515 @default.
• W3022969440 hasAuthorship W3022969440A5087968813 @default.
• W3022969440 hasAuthorship W3022969440A5090087138 @default.
• W3022969440 hasBestOaLocation W30229694402 @default.
• W3022969440 hasConcept C126322002 @default.
• W3022969440 hasConcept C134018914 @default.
• W3022969440 hasConcept C207103383 @default.
• W3022969440 hasConcept C2777180221 @default.
• W3022969440 hasConcept C2777214474 @default.
• W3022969440 hasConcept C2778019345 @default.
• W3022969440 hasConcept C2778721985 @default.
• W3022969440 hasConcept C2778772119 @default.
• W3022969440 hasConcept C2779134260 @default.
• W3022969440 hasConcept C2779478299 @default.
• W3022969440 hasConcept C2780323712 @default.
• W3022969440 hasConcept C44249647 @default.
• W3022969440 hasConcept C50382708 @default.
• W3022969440 hasConcept C555293320 @default.
• W3022969440 hasConcept C71924100 @default.
• W3022969440 hasConcept C90924648 @default.
• W3022969440 hasConceptScore W3022969440C126322002 @default.
• W3022969440 hasConceptScore W3022969440C134018914 @default.
• W3022969440 hasConceptScore W3022969440C207103383 @default.
• W3022969440 hasConceptScore W3022969440C2777180221 @default.
• W3022969440 hasConceptScore W3022969440C2777214474 @default.
• W3022969440 hasConceptScore W3022969440C2778019345 @default.
• W3022969440 hasConceptScore W3022969440C2778721985 @default.
• W3022969440 hasConceptScore W3022969440C2778772119 @default.
• W3022969440 hasConceptScore W3022969440C2779134260 @default.

• next